The nocebo effect challenges the non-medical infliximab switch in practice
Open accessThe DOI matches its Crossref record.
Abstract
BACKGROUND: In clinical practice, non-medical switching of biological medication may provoke nocebo effects due to unexplained deterioration of therapeutic benefits. Indication extrapolation, idiosyncratic reactions, and interchangeability remain challenged in clinical practice after biosimilar approval by the European Medicines Agency. The principle of "first do no harm" may be challenged in a patient when switching from originator to biosimilar biological. AIM: To describe the 1-year results of a pragmatic study on infliximab biosimilar implementation in immune-mediated inflammatory disease patients on the basis of shared decision-making under effectiveness and safety monitoring. METHODS: Inflammatory bowel disease and rheumatology patients on infliximab originator were converted to infliximab biosimilar after providing informed consent. Nocebo response patients were monitored after switch back to originator. Linear mixed models were used to analyze continuous endpoints on effectiveness and laboratory outcomes to determine significance (P ≤ 0.05) of change over time after switching. RESULTS: After inviting 146 patients, a group of 125 patients enrolled in the project over time, respectively, 73 Crohn's disease, 28 ulcerative colitis, nine rheumatoid arthritis, ten psoriatic arthritis, and five ankylosing spondylitis patients. No statistically significant changes in effectiveness and safety were observed in any of the indications after a median of 4 infusions in 9 months of study. An overall nocebo response of 12.8% was found among the patients during a minimal observation period of 6 months after the transition to biosimilar infliximab. The overall nocebo response rate did not differ between the studied indications. CONCLUSIONS: In inflammatory bowel disease and rheumatological patients, similar effectiveness and safety were demonstrated on the transition into infliximab biosimilar. In our series, patient empowerment and registration of treatment outcomes delineated biosimilar transition, an approach that hypothetically could reduce nocebo response rates which are relevant to account for regarding biosimilar implementation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Petrie, K. J., & Rief, W. (2019) · Annual Review of Psychology · doi:10.1146/annurev-psych-010418-102907 · Cited by 309
“Drug switches from branded to generic can result in increased reports of side effects and complaints that the new drug is less effective (Boone et al. 2018, Weissenfeld et al. 2010).”
Background(2019) · doi:10.32872/cpe.v1i1.29642 · Cited by 24
Meijboom, R. W., Gardarsdottir, H., Egberts, T. C. G., & Giezen, T. J. (2022) · BioDrugs · doi:10.1007/s40259-021-00508-4 · Cited by 18
Metadata
- Authors
- Boone, N. W., Liu, L., Romberg-Camps, M. J., Duijsens, L., Houwen, C., van der Kuy, P. H. M., Janknegt, R., Peeters, R., Landewé, R. B. M., Winkens, B., & van Bodegraven, A. A.
- Venue
- European Journal of Clinical Pharmacology
- Published
- 2018-01-24
- Volume
- 74
- Issue
- 5
- Pages
- 655-661
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W2784409714
- Cited by
- 118
- References
- 0
- FWCI
- 6.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The nocebo effect challenges the non-medical infliximab switch in practice. https://app.cochat.ai/papers/10.1007/s00228-018-2418-4
- The paper
- Boone, N. W., Liu, L., Romberg-Camps, M. J., Duijsens, L., Houwen, C., van der Kuy, P. H. M., Janknegt, R., Peeters, R., Landewé, R. B. M., Winkens, B., & van Bodegraven, A. A. (2018). The nocebo effect challenges the non-medical infliximab switch in practice. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-018-2418-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.